Valneva (NASDAQ:VALN) Trading Down 4.6%

Valneva SE (NASDAQ:VALNGet Free Report) shares traded down 4.6% during trading on Tuesday . The stock traded as low as $8.43 and last traded at $8.43. 2,692 shares changed hands during trading, a decline of 76% from the average session volume of 11,225 shares. The stock had previously closed at $8.84.

Analyst Ratings Changes

Several analysts recently commented on the company. Guggenheim dropped their price target on Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 22nd. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Valneva in a research report on Thursday.

Read Our Latest Analysis on VALN

Valneva Price Performance

The company has a quick ratio of 2.22, a current ratio of 2.64 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $607.96 million, a PE ratio of -21.29 and a beta of 2.22. The company has a 50-day moving average of $7.93 and a 200 day moving average of $9.06.

Valneva (NASDAQ:VALNGet Free Report) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). The company had revenue of $45.12 million for the quarter, compared to analyst estimates of $45.06 million. Valneva had a negative return on equity of 14.56% and a negative net margin of 15.88%. Sell-side analysts predict that Valneva SE will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. grew its holdings in Valneva SE (NASDAQ:VALNFree Report) by 2.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the period. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 as of its most recent filing with the Securities & Exchange Commission. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

Further Reading

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.